Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$450.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Tao Fu
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 44
- Beta
- 0.00
- Country
- US
Financials
ATTO has only 3 quarterly periods on file — the charts below show the full history available.
Revenue
$450.0K+0.0%Net Income
$-20.69MEBITDA
$-21.56MFree Cash Flow
$-16.86MEPS (diluted)
$-0.45Shares Outstanding (diluted)
45.65M+18.5%Operating Expenses
$22.01MCash & Debt
$115.13MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.35M | $-60.63M | $-1.42 |
| 2024 | $0.00 | $-39.80M | $-1.05 |
Valuation
ATTOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (4)
- Newsglobenewswire.com·7d ago·Neutral
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Aca…
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
Attovia Therapeutics to Participate in Upcoming Investor Conferences SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:
View source ↗ - Newsglobenewswire.com·33d ago·Neutral
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026
View source ↗ - News247wallst.com·50d ago·Neutral
Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source Attovia Therapeutics (NASDAQ:ATTO) has arrived on public markets with a pipeline built entirely on one bet: that a biparatopic antibody platform called Attobody can turn well-validated immunology targets into next-generation biologics.
View source ↗
Earnings
Typical surprise -655.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Sep 2$-4.88 vs $-0.65miss
Estimates and results for ATTO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ATTO officers and directors.
- Bought
- $52.4m
- Sold
- $4.5m
21 trades
46 trades
- Walsh Colinbought
- Goldman Sachs Group Incbought
- Venbio Global Strategic Fund Iv, L.p.bought
- Redmile Group, Llcbought
- Redmile Group, Llcbought
- Sanofibought
- Frazier Life Sciences Xi, L.p.bought
- Walsh Colinbought
33 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ATTO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.